Effectiveness of primary endocrine therapy in older adults with estrogen receptor-positive breast cancer: A real-world audit of a dedicated primary endocrine therapy clinic
Breast cancer incidence rises steeply with age; in the United Kingdom a quarter of new diagnoses occur in women aged 75 years and over, a group frequently characterised by frailty, multimorbidity, and heightened surgical risk [1–3]. Primary endocrine therapy (PET), the use of endocrine agents without surgical intent as the primary local treatment for hormone receptor-positive disease, is an established option for those unsuitable for or declining surgery, with aromatase inhibitors, particularly letrozole, now the first-line agents [4].
Authors
- Rachel L. O’Connell (ORCID: https://orcid.org/0000-0001-5990-8142)
- Kate Downey (ORCID: https://orcid.org/0000-0002-2498-4257)
- Nikki Snuggs
- Peter A. Barry (ORCID: https://orcid.org/0000-0003-0809-7452)
- Serene Si Ning Goh (ORCID: https://orcid.org/0000-0003-4916-2142)
- Amy R. Godden (ORCID: https://orcid.org/0000-0001-9781-6097)
- Rebekah Law (ORCID: https://orcid.org/0000-0001-9248-605X)
- Quratul Ain (ORCID: https://orcid.org/0000-0002-3913-9857)
- Katherine Krupa (ORCID: https://orcid.org/0009-0006-1122-6445)
- Mohamed Attia
- Hani Maalouf
Institutions
- Institute of Cancer Research (GB)
- Royal Marsden Hospital (GB)
- National University Hospital (SG)
Publication Details
- Journal
- Journal of Geriatric Oncology
- Published
- 2026-10-28
- DOI
- https://doi.org/10.1016/j.jgo.2026.104657
- Primary Topic
- Breast Cancer Treatment Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00